CyclopharmASX:CYC 46 EV-to-FCF is -3.30 as of Jun. 28, 2026. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 75 Medical Distribution companies, Cyclopharm ranks worse than 1333332% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cyclopharm's Enterprise Value is A$64.15 Mil.
Cyclopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-19.44 Mil. Therefore, Cyclopharm's EV-to-FCF for today is -3.30.
The historical rank and industry rank for Cyclopharm's EV-to-FCF or its related term are showing as below:
ASX:CYC'
s EV-to-FCF Range Over the Past 10 Years
Min: -178.16 Med: -26.13 Max: 21.16
Current: -3.3
During the past 13 years, the highest EV-to-FCF of Cyclopharm was 21.16. The lowest was -178.16. And the median was -26.13.
ASX:CYC's EV-to-FCF is ranked worse than 100% of 75
companies
in the Medical Distribution industry
Industry Median: 16.04
vs ASX:CYC: -3.30
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cyclopharm's share price for today is A$0.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.157.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cyclopharm EV-to-FCF Related Terms
Cyclopharm EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cyclopharm's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cyclopharm's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cyclopharm's EV-to-FCF falls into.
Cyclopharm's current Enterprise Value is A$64.15 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-19.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a EV-to-FCF of -3.30 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cyclopharm and its competitors. According to the industry distribution chart, Cyclopharm ranks #999999 out of 75 companies in the Medical Distribution industry.
Is Cyclopharm's EV-to-FCF too high?
Cyclopharm's current EV-to-FCF is -3.30. Based on the distribution chart, Cyclopharm ranks #999999 out of 75 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's EV-to-FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #999999 out of 75 companies for EV-to-FCF. This places Cyclopharm in the lower half of its industry. The industry median EV-to-FCF is 16.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 16.04, based on 75 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cyclopharm and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 16.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current EV-to-FCF is -3.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current EV-to-FCF is -3.30. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current EV-to-FCF is -3.30 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
EV-to-FCF: -3.30
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
46GF Score
Get the complete analysis for ASX:CYC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
